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Chicago, Illinois.BACKGROUND Insertable cardiac monitors (ICMs) are used for
long-term ECG monitoring. The Reveal LINQ ICM has an improved
atrial ﬁbrillation (AF) detection algorithm.
OBJECTIVE The purpose of this study was to investigate the
algorithm’s real-world performance in patients with syncope,
cryptogenic stroke, and known AF.
METHODS Consecutive patients with implanted ICM and AF detec-
tion parameters automatically set and maintained depending on
the indication for monitoring were included. A single reviewer
annotated all stored episodes after ICM implant. A second reviewer
annotated a random sample of 10% of all detected AF episodes. The
episode detection positive predictive value as well as true and false
detection rates were determined for AF episodes of different
durations.
RESULTS The study enrolled 3759 patients (1604 [43%] with
syncope, 1049 [28%] with known AF, 1106 [29%] with cryptogenic
stroke). Overall, 20,659 AF episodes were detected in 1020
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1547-5271/$-see front matter B 2016 Heart Rhythm Society. All rights reserved.was 84%, 73%, and 26% for all episodes (≥2 minutes) and
improved to 97%, 95%, and 91% for detected AF episodes ≥1 hour
in the syncope, known-AF, and cryptogenic stroke patient cohorts,
respectively. The true (and false) detection rate was 0.23 (0.05),
3.8 (1.4), and 0.23 (0.65) per patient-month of monitoring for the
syncope, known-AF, and cryptogenic stroke patient cohorts,
respectively. Limiting ECG storage to the longest detected AF
episode signiﬁcantly reduced the burden of episode adjudication
without signiﬁcantly compromising the identiﬁcation of patients
with true AF.
CONCLUSION The performance of LINQ ICM is dependent on the AF
incidence rate in the population being monitored, the programmed
sensitivity of AF algorithm, and the duration of detected AF
episodes.
KEYWORDS Atrial ﬁbrillation; Insertable cardiac monitor; Diagnosis
and monitoring
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Subcutaneous insertable cardiac monitors (ICMs) use inco-
herence of R-R intervals over a period of time to detect atrial
ﬁbrillation (AF).1 Although not as accurate as implantable
devices that incorporate a sensing lead in the right atrium,2
ICMs still have been shown to have high accuracy in
detecting AF.1,3 Continuous long-term ECG monitoring
provided by ICMs improves the ability to diagnose the
presence or absence of AF compared with intermittent ECG
monitoring tools such as Holter monitoring4,5 or reliance on
patient symptoms alone.6 ICMs have been used for diagnos-
ing and monitoring of recurrent AF after surgical and
catheter ablation of AF,5,7–9 catheter ablation of atrialﬂutter,10 and in patients with history of cryptogenic
stroke.11,12 However, a perceived high rate of inappropriate
AF detection, especially in patients with low incidence of
AF, has been considered an impediment for routine use of
ICMs.9 Yet, these are the patients who are most likely to
beneﬁt from continuous and long-term ECG recordings
compared with short-term external ECG monitoring.
To date, much of the diagnostic utility of ICMs has been
derived from studies using the Reveal XT (Medtronic,
Minneapolis, MN) ICM. Recently, a second-generation
ICM (Reveal LINQ, Medtronic) has become commercially
available. This device was developed with a better electrode
coating and novel implant technique to improve the quality
of the recorded ECG signal. In addition, the device features
an improved AF detection algorithm based on the recog-
nition of a single P wave between 2 R waves using
morphologic processing of the ECG signal. When evaluated
against the original device algorithm using 48-hour Holter
recordings in a population with known paroxysmal AF, the
new algorithm was shown to improve speciﬁcity and positivehttp://dx.doi.org/10.1016/j.hrthm.2016.05.010
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sensitivity.13 The main objective of this study was to
evaluate the real-world AF episode detection performance
in the LINQ ICM over follow-up in a large cohort of patients
undergoing ECG monitoring for various indications.
Methods
Study cohort
All consecutive patients implanted with a Reveal LINQ ICM
device with at least 3 months of follow-up postimplant were
selected from the de-identiﬁed Medtronic Discovery Link
database. All patients provided consent to use their device
data for research purposes. In this study, we included patients
with unexplained syncope, cryptogenic stroke, and known
AF who underwent LINQ implantation for long-term ECG
monitoring. Table 1 lists the automatically programmed AF
detection settings for the different indications for ICM
implant, which is based on the expected incidence rate of
AF and the clinical relevance of AF detection in the patient
population. (We excluded all patients not programmed
according to the recommended AF detection settings.)
Programming was optimized to maintain high speciﬁcity
(accepting somewhat lower sensitivity) in patients with
unexplained syncope. In contrast, in patients with crypto-
genic stroke, programming was guided by the need to
maintain as high sensitivity as possible, even for very short
duration episodes of AF (thus accepting somewhat lower
speciﬁcity).
AF detection algorithm
In an ICM, AF detection is based on incoherence of R-R
intervals.1 This algorithm was prospectively evaluated in the
XPECT study using Reveal XT devices.3 The R-R interval–
based algorithm was recently enhanced by incorporating
P-wave evidence information in Reveal LINQ devices.13
The P-wave evidence mode (off, nominal, and aggressive)
and the detection threshold (more sensitive, balanced sensi-
tivity, less sensitive, and least sensitive) are programmable
parameters, which can be used to tailor the detection
sensitivity and speciﬁcity of the AF algorithm to the clinical
indication for ECG monitoring (Table 1).13
The AF detection algorithm makes a decision every 2
minutes. If an episode is detected as AF, the ﬁrst 2 minutes of
ECG from that episode can be stored in the device. TheTable 1 Nominal atrial ﬁbrillation detection programming based on th
AF detection programming in ICM
Indication for ICM implan
Syncope
AF detection type AF only*
AF detection sensitivity Least sensitive*
Ectopy rejection Aggressive*
ECG storage Longest episode only†
AF ¼ atrial ﬁbrillation; ICM ¼ insertable cardiac monitor.
⁎All patients had to be programmed in this mode for inclusion in data cohort.
†Not all patients had to be programmed in this mode for inclusion in data cohortdevice can store up to 14 AF episodes with an ECG, after
which the most recent AF episode overwrites the earliest AF
episode. ECG data from the longest detected AF episode
(≥10 minutes) since the last full manual transmission is
always preserved in memory. After the next full manual
transmission, the device will restart, looking for the new
longest episode. The patient can manually transmit full
information on all stored episodes at any time. Additionally,
every night the Reveal LINQ device automatically and
wirelessly transmits the last 10 seconds of the 2-minute
ECG segment from the longest episode (at least ≥10 minutes
or per duration-based episode storage programming
described later) of AF observed during that day and stored
in device memory.
The device can store ECG information on all detected
episodes of AF (by design, these episodes must be ≥2
minutes), as described earlier. However, the device also
provides additional programmable options to preserve ECG
storage memory. Speciﬁcally, the clinician can program the
device to store ECG only for AF episodes ≥6 minutes, ≥10
minutes, ≥ 30minutes, or ≥60 minutes. A ﬁnal option allows
one to restrict ECG storage to only the longest AF episode;
however, the longest AF episode must be ≥10 minutes.
Thus, if one chooses to store ECG only for episodes ≥10
minutes, the device will only log and store ECG information
for up to the last 14 episodes that have duration ≥10 minutes,
in addition to the longest AF episode. The device will still
detect episodes (but not log or store the ECG) of shorter
durations (o10 minutes) and add them to cumulative total
duration of detected AF (AF burden). If one chooses to only
store the longest AF episode, then at any given time only 1
episode (≥10 minutes) is stored in device memory. Only the
longest episode stays in device memory until a new episode
that is longer in duration is detected by the device or the
episode in memory is transmitted by a full manual download
of the device.Episode annotation
All episodes collected by the device during the ﬁrst 3 months
after implant that were stored with either a 10-second or a
2-minute ECG segment were reviewed by a single reviewer
(SS). A random sampling of 10% of episodes was re-
reviewed by the same reviewer to determine intrareviewer
variability. Another 10% random sample was reviewed by ae indication for insertable cardiac monitor implant
t
Known AF Cryptogenic stroke
AF only* AF only*
Balanced sensitivity* Balanced sensitivity*
Nominal* Aggressive*
All episodes† All episodes†
.
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was blinded to the patient’s indication for ICM implantation.
Any discordance between the ﬁrst and second reviewers was
adjudicated by a third reviewer (RSP; board-certiﬁed electro-
physiology attending) to ascertain the inter-reviewer varia-
bility. Episodes were considered to be true if there was a ≥10-
second ECG segment showing an atrial tachycardia or AF.
Statistical analysis
AF episode detection PPV was computed as the ratio of the
total number of AF episodes in all patients that were
annotated to be true and the total number of AF episodes
that were detected by the device and stored with an ECG in
all patients. Patient average episode detection PPV, which
averages the effect of multiple episodes in patients, was
evaluated by computing the episode detection PPV for each
patient and then averaging across all patients. Episode
detection sensitivity cannot be computed in this dataset
because there is no knowledge about true AF episodes that
were not detected by the device (i.e., false-negative episodes
are not recorded in this dataset). Episode detection speciﬁcity
and negative predictive value cannot be deﬁned because a
true negative episode cannot be deﬁned in this dataset. True
and false episode detection rates were computed as the total
number of appropriate and inappropriate detections per
month during the entire follow-up duration of 3 months for
each patient. True and false detection rates for each patient
were then averaged across all patients to estimate the mean
true and false detection rates. Episode detection PPV and true
and false detection rates are separately reported for the 3
patient populations: patients with unexplained syncope,
cryptogenic stroke, or known AF. Within each patient
population, the performance metrics were determined as a
function of the duration of detected episode.Results
The study enrolled 3759 patients, including 1604 (43%) with
unexplained syncope, 1106 (29%) with cryptogenic stroke,
and 1049 (28%) with known AF (Table 2). In the ﬁrst 3
months postimplant, the ICMs recorded a total of 20,659 AFTable 2 Long-term episode detection performance for different patien
Syncope
No. of patients 1604
Age (years) 63 ± 19
Male gender (%) 44
No. of detected AF episodes 1346
No. with a true AF episode 1124 (84%)
Patients with a detected AF episode 192 (12%)
Patients with true AF episodes 156 (81%)
True-positive rate (per patient-month) 0.23
False-positive rate (per patient-month) 0.05
Positive predictive value (raw) 84%
Positive predictive value (patient average) 80%
AF ¼ atrial ﬁbrillation.episodes. Not surprisingly, AF was most commonly
recorded in patients with known AF. These patients
accounted for 16,506 (80%) of all recorded AF episodes.
The ﬁrst reviewer re-reviewed a random sample contain-
ing 10% of all detected events. In 499% of instances, the
initial and second reviews classiﬁed the events similarly.
A second reviewer reviewed a random sample of 2230
episodes. Overall, 2216 of these events (99.4%) were
classiﬁed similar to the ﬁrst reviewer.
AF episode detection performance during long-term
follow-up is given in Table 2. For all detected episodes with
an associated stored ECG available for review, the raw (and
average of per-patient) episode detection PPV, or the
proportion of all reviewed episodes that was true atrial
tachycardia or AF, was 84% (80%), 73% (73%), and 26%
(33%) for the syncope, known-AF, and cryptogenic stroke
patient cohorts, respectively.
The rate of detection of true episodes of AF was much
higher in the known-AF patient cohort (3.8 episodes per
patient-month) compared to the syncope and cryptogenic
stroke patient cohorts; both of these cohorts had 0.23 true AF
episodes per patient-month of monitoring. The rate of
detection of false AF episodes was also highest in the
known-AF patient cohort (1.4 episodes per patient-month).
The rate was lower in the cryptogenic stroke patient cohort
(0.65 episodes per patient-month) and lowest in the syncope
patient cohort (0.05 episodes per patient-month). Thus, if an
implanting center had 100 patients with an ICM for each of
the 3 indications, one could expect to receive 520, 88, and 28
detected (true þ false) AF episodes (with an available stored
ECG) each month in the known-AF, cryptogenic stroke, and
syncope patient cohorts, respectively. Of these detections,
140 (27%), 65 (74%), and 5 (18%) episodes in each of the
respective cohorts would be for an inappropriate detection of
AF.
The true- and false-positive AF detection rates are a
function of the relative incidence rates of AF in these patient
cohorts as well as the programmed settings for AF detection
(Table 1). Of note, although the cryptogenic stroke patient
cohort has a lower PPV (26%) compared to the known-AF
patient cohort (73%), the absolute rate of inappropriate AF
detections is much lower in the cryptogenic stroke patientt cohorts for all detected atrial ﬁbrillation episodes
Known AF Cryptogenic stroke
1049 1106
66 ± 11 65 ± 14
63 52
16,506 2807
11,974 (73%) 720 (26%)
605 (58%) 223 (20%)
494 (82%) 87 (39%)
3.8 0.23
1.4 0.65
73% 26%
73% 33%
Figure 1 Long-term atrial ﬁbrillation (AF) episode detection performance as a function of detected AF episode duration and stratiﬁed by patient cohort.
A: True-positive episode detection rate. B: False-positive episode detection rate. C: Raw positive predictive value for episode detection. The longest episode
storage setting keeps in memory only the longest AF detected episode that is ≥10 minutes since the last full manual transmissions. D: Episode detection yield
represented as percentage of patients with detected and true episodes for the different episode detection settings.
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patient cohort (1.4 per patient month). The lower PPV in the
cryptogenic patient cohort is primarily driven by the lower
incidence rate of AF.
The true-positive and false-positive episode AF detection
rate as well as the raw PPV of episode detection as a function
of detected episode duration are shown in Figures 1A, 1B,
and 1C, respectively. The true- and false-positive detection
rate reduces as a function of the detected episode duration.
Net reclassiﬁcation indices as a function of episode duration
are presented in the Online Supplemental Appendix. The
episode detection PPV improves with increased detected
episode duration, with 97%, 95%, and 91% of detected AF
episodes ≥1 hour in duration being true in the syncope,
known-AF, and cryptogenic stroke cohorts, respectively.
The episode detection yield as a function of the pro-
grammed episode duration for detection is given in Table 3.
For example, in the known-AF patient cohort, choosing to
review only AF episodes ≥10 minutes or only the longest
episode reduces the number of episodes needing review from
16,506 to 9030 (relative reduction of 45%) or 2990 (relative
reduction of 82%), respectively (Table 3 and Figure 1D). If
the ≥10-minute approach was adopted, true AF would be
missed in only 26 (relative reduction of 5%) of 494 patients
with an additional loss of 2 patients if the longest episode
was chosen. However, in these patients, all detected AF
episodes were o10 minutes in duration (2.4 episodes per
patient with mean duration of 2.9 minutes per episode).
Furthermore, it should be acknowledged that in a small
cohort of patients, there would be a slight delay in diagnosisof AF. Of the 468 patients in whom at least 1 episode of AF
≥10 minutes was detected, 101 patients (20%) had an initial
AF episode that was o10 minutes. These patients subse-
quently had a longer episode in a median of 10 hours
(interquartile range 0.5–187 hours).
Similarly, in the cryptogenic stroke patient cohort,
choosing to only review AF episodes ≥10 minutes or the
longest episode reduces the number of episodes needing
review from 2807 to 990 (relative reduction of 65%) or 418
(relative reduction of 85%), respectively (Table 3 and
Figure 1D). If either approach was adopted, true AF would
be missed in 14 (relative reduction of 16%) of 87 patients
(with no additional loss going to the longest episode) with
true episodes of AF; however, in these patients, all detected
AF episodes wereo10 minutes in duration (2.4 episodes per
patient with mean duration of 2.9 minutes per episode).
Furthermore, in a small cohort of patients, there would be
slight delay in diagnosis of AF. Of the 73 patients in whom at
least 1 episode of AF ≥10 minutes was detected, 7 patients
(8%) had an initial AF episode that waso10 minutes. These
patients subsequently had a longer episode in a median of
280 hours (interquartile range 10-492 hours). Figure 2 shows
the Kaplan–Meier estimates for true AF detection rates
illustrating the loss and delay in diagnostic yield in the
cryptogenic stroke patient cohort.
Inappropriate episode detection was caused by various
physiologic (e.g., runs of ectopy with irregular coupling, sick
sinus, sinus tachycardia) and nonphysiologic reasons (e.g.,
oversensing or undersensing). In the syncope, known-AF,
and cryptogenic stroke patient cohorts, 100%, 94%, and 97%
Table 3 Episode detection yield for different patient cohorts as a function of duration of detected atrial ﬁbrillation episode over 3-month
postimplant follow-up period
Indication for ICM implant
Detected episode
duration groups
No. of
episodes
No. of true
episodes (PPV)
No. of patients with
episodes (%)
No. of patients with
true episodes (%)
Syncope (N ¼ 1604 patients) All 1346 1124 (84%) 192 (12%) 156 (81%)
≥6 min 1336 1114 (83%) 192 (12%) 156 (81%)
≥10 min 1288 1082 (84%) 192 (12%) 156 (81%)
≥30 min 1029 955 (93%) 155 (10%) 141 (91%)
≥1 hour 873 844 (97%) 134 (8%) 128 (96%)
Longest 865 749 (87%) 192 (12%) 156 (81%)
Known AF (AF ablation/
management) (N ¼ 1049
patients)
All 16,506 11,974 (73%) 605 (58%) 494 (82%)
≥6 min 10,555 8601 (81%) 555 (53%) 473 (85%)
≥10 min 9030 7555 (84%) 537 (51%) 468 (87%)
≥30 min 5801 5313 (92%) 468 (45%) 436 (93%)
≥1 hour 4277 4063 (95%) 419 (40%) 401 (96%)
Longest 2990 2527 (85%) 537 (51%) 466 (87%)
Cryptogenic stroke (N ¼ 1106
patients)
All 2807 720 (26%) 223 (20%) 87 (39%)
≥6 min 1308 515 (39%) 148 (13%) 75 (51%)
≥10 min 990 456 (46%) 132 (12%) 73 (55%)
≥30 min 452 351 (78%) 82 (7%) 64 (78%)
≥1 hour 318 288 (91%) 65 (6%) 59 (91%)
Longest 418 195 (47%) 132 (12%) 73 (55%)
AF ¼ atrial ﬁbrillation; ICM ¼ insertable cardiac monitor; PPV ¼ positive predictive value.
Heart Rhythm, Vol 13, No 8, August 20161628of inappropriate detections, respectively, were primarily due
to physiologic reasons.Discussion
There are several important ﬁndings of this study, which
evaluated the real-world performance of the LINQ ICM with
an enhanced AF detection algorithm in 3 distinct patient
cohorts. First, the episode PPV for any detected AF episode
of ≥1-hour duration is490%, irrespective of indication for
long-term ECG monitoring. Second, for short-duration
episodes of AF, the episode detection performance is
dependent on the incidence rate of AF in the patient
population being monitored and the duration of each
detected AF episode. The performance is most problematic
in cohorts such as those with cryptogenic stroke in which theFigure 2 Kaplan–Meier estimates for true atrial ﬁbrillation (AF) detection
rates illustrate the loss and delay in diagnostic yield in the cryptogenic stroke
patient cohort.incidence rate of AF is low yet the device by design is
programmed to favor very high sensitivity for AF detection.
Third, in patients with known AF, despite the high episode
PPV, the high incidence rate of AF generates a high volume
of detected AF episodes that require adjudication. Finally,
the LINQ ICM offers the opportunity to limit ECG storage to
the longest detected AF episode. Incorporation of this
programming option can signiﬁcantly reduce the burden of
AF episode adjudication without signiﬁcantly compromising
the identiﬁcation of patients with true AF, particularly in
clinical situations in which identiﬁcation of short-duration
episodes may not be clinically relevant.
ICMs are increasingly being used for long-term ECG
monitoring in patients with suspected or known history of
AF.7–10 In these patients, the goal of the AF detection
algorithm not only is identify which patients are having AF
but also to quantify accurately the type and amount of AF
and the average ventricular rate during the entire duration of
AF such that appropriate clinical management decisions can
be taken in a timely manner. Although there is no consensus
regarding clinically relevant duration of AF, several studies
have shown an association between the amount of AF and
increased risk of stroke14,15 and risk for heart failure
events,16 suggesting that the amount of AF is clinically
relevant.
The episode detection PPV improves with duration of
detected episode. The basic reason is that causes of false AF
detection, such as runs of ectopy with irregular coupling, are
sporadic in nature and do not persist over a long time in
contrast to true AF. Hence, longer episodes are more likely to
be true AF episodes. The clinical burden inherent to the need
to adjudicate episodes of AF has been a limitation to the
routine use of ICMs for diagnosis of AF in all patient
cohorts. One way to reduce episode review burden is to
review only longer AF episodes.
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with cryptogenic stroke.11,12 The goal is to identify patients
who have AF and initiate anticoagulation treatment to
prevent a secondary stroke. Additionally, by limiting anti-
coagulation to patients with documented AF, patients with-
out an indication for anticoagulation are spared the risk of
bleeding inherent to these medications. By design, the ICM
is programmed to favor high sensitivity in these patients.
However, given the low incidence rate of AF in these
patients, the result is low episode detection PPV. On the
other hand, in patients with known AF, a very high number
of AF episodes is detected. In both clinical scenarios, a great
deal of time and effort is needed to adjudicate the stored
electrograms.
We suggest a new programming strategy in patients being
implanted with a LINQ ICM in whom therapeutic decisions
will not be altered based on short episodes of AF (o10
minutes). Instead of storing the ECG for all detected AF
episodes, ECG storage is limited to the longest episode of
AF. By design, when this programming option is chosen, the
device stores the ECG for the longest AF episode lasting ≥10
minutes. This signiﬁcantly reduces the number of AF
episodes that require adjudication, with only a small loss in
diagnostic yield. However, it is important to recognize that
the small number of patients in whom all AF episodes are
o10 minutes will be “missed” by this approach. In some
patients, there may be a slight delay in the diagnosis of AF;
however, whether this delay adversely impacts clinical
outcomes remains unclear. At any time, a manual trans-
mission can be requested to “reset” the longest AF duration
counter. This is useful when (1) an intervention is made (e.g.,
antiarrhythmic drug initiated, catheter ablation performed,
anticoagulation stopped) and (2) review of the longest AF
episode shows it to be a false detection and identiﬁcation
of a true episode of that duration would alter clinical
management.
Our data show that when AF episodes last ≥1 hour, PPV
increases to 95%. This long duration cutoff may be entirely
acceptable in a cohort of patients with known AF, as shorter
duration episodes may not impact clinical decision-making.
Two recent studies have investigated whether patients with
known AF can be managed by using the ICM to determine if
they are or are not having AF episodes ≥1 hour. Zuern et al17
investigated 65 patients with a CHADS2 score between 1 and
3 who remained free of AF 3 months after catheter ablation.
An ICM was implanted and interrogated daily to determine
whether there was ≥1-hour AF. Anticoagulation was ini-
tiated only if AF ≥1 hour was detected. During follow-up of
32 ± 12 months, anticoagulation was withheld in 41 patients
(63%); no stroke, transient ischemic attack, or other throm-
boembolic event was observed. Passman et al18 investigated
59 patients with nonpermanent AF and CHADS2 score of 1
or 2. After ICM implantation, anticoagulation was with-
drawn if no episodes of AF ≥1 hour were observed in the
ﬁrst 60 days. If an AF episode ≥1 hour was detected by the
ICM, anticoagulation was reinitiated for 30 days and then
stopped as long as no additional episodes of AF occurred.This “pill-in-the-pocket” method of anticoagulation reduced
the cohort’s exposure to an anticoagulant by 94%; no strokes
or deaths were observed in this pilot study.
Study limitations
The main limitation of the study is that episode detection
sensitivity cannot be ascertained because information about
occurrences of underdetected AF is not available with the
current design of the real-world Reveal LINQ ICM study.
Only studies using concomitant external Holter monitoring
(typically feasible only over a short follow-up) can deﬁne the
true sensitivity for AF detection.19 Second, only short ECG
segments (either 10 seconds or 2 minutes at the onset) were
available to help adjudicate the AF episodes. Thus, it was
necessary to assume that the ECG at onset represented the
rhythm for the entire duration of the detected AF episode.
Nonetheless, we were able to show a high degree of
intraobserver and interobserver reproducibility for adjudica-
tion of ICM-detected events.
Conclusion
The episode detection performance of Reveal LINQ ICM is
excellent in all patients for AF episodes lasting 1 hour or
more. For shorter-duration episodes, the ICM’s performance
is dependent on the incidence rate of AF in the patient
population being monitored. Furthermore, the programmed
sensitivity of the AF detection algorithm optimizes the
episode detection performance depending on the clinical
relevance of AF diagnosis in the patient being monitored.
Episode adjudication burden can be reduced signiﬁcantly
(with a small relative compromise or delay in diagnostic
yield) by limiting storage to only the longest detected
episode in clinical scenarios in which short-duration epi-
sodes are not clinically relevant. Our data have important
implications for programming of the LINQ ICM, which may
translate into more efﬁcient follow-up of patients with these
devices.
Appendix
Supplementary data
Supplementary data associated with this article can be found
in the online version at http://dx.doi.org/10.1016/j.hrthm.
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